Florian Simon Ritter-Linke, Lisa-Marie Geberth, Alexander Carl Geberth
{"title":"In correspondence to \"Timely integration of palliative care. the reality check. a retrospective analysis\" by Adamidis et al. [1]\".","authors":"Florian Simon Ritter-Linke, Lisa-Marie Geberth, Alexander Carl Geberth","doi":"10.1007/s00520-024-08967-5","DOIUrl":"https://doi.org/10.1007/s00520-024-08967-5","url":null,"abstract":"","PeriodicalId":22046,"journal":{"name":"Supportive Care in Cancer","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142584379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Emily N Larsen, Claire M Rickard, Nicole Marsh, Mary Fenn, Rebecca S Paterson, Amanda J Ullman, Raymond J Chan, Vineet Chopra, Doreen Tapsall, Amanda Corley, Nicole Gavin, Brighid Scanlon, Joshua Byrnes
{"title":"Patient reported outcome and experience measures among patients with central venous access devices: a systematic review.","authors":"Emily N Larsen, Claire M Rickard, Nicole Marsh, Mary Fenn, Rebecca S Paterson, Amanda J Ullman, Raymond J Chan, Vineet Chopra, Doreen Tapsall, Amanda Corley, Nicole Gavin, Brighid Scanlon, Joshua Byrnes","doi":"10.1007/s00520-024-08961-x","DOIUrl":"https://doi.org/10.1007/s00520-024-08961-x","url":null,"abstract":"<p><strong>Purpose: </strong>Patients receiving treatment for solid tumours and haematological malignancies, among other acute and chronic health conditions, are highly dependent upon central venous access devices (CVADs) for administering chemotherapy and other complex therapies; thus, CVADs can meaningfully impact their health outcomes and experiences. This systematic review aimed to identify and critique patient-reported outcome measure (PROM) and patient-reported experience measure (PREM) instruments related to CVADs.</p><p><strong>Methods: </strong>A systematic review was undertaken, commencing with an electronic search of health databases (April 2022). Studies were eligible if they used a self-reporting instrument (questionnaire) to quantitatively measure patient-reported outcomes and experiences related to CVADs (English only). Using a piloted data-extraction tool, two authors independently identified studies for full review, data extraction, and quality assessment. Data were synthesised narratively.</p><p><strong>Results: </strong>The search yielded 875 titles, of which 41 met the inclusion and no exclusion criteria. Of these, 31 reported results of purpose-built questionnaires; a further six reported results of generic measures used for CVADs; four included both purpose-built and generic measures. Overall study quality was low; only two studies evaluated both content validity and internal consistency. In total, 155 unique PROM items (across 27 studies) were extracted which encompassed five domains (e.g., 'Instrumental activities of daily living'; 'Pain and discomfort'). Similarly, 184 unique PREMs (from 31 studies) included 13 domains (e.g., 'Shared decision-making'; 'Education').</p><p><strong>Conclusion: </strong>Increasingly, research and quality improvement studies about CVADs are incorporating PROM and PREM. These measures are largely purpose-built, however, and their validity and reliability have not been sufficiently established for use.</p><p><strong>Review registration: </strong>Prospectively submitted to the International prospective register of systematic reviews (PROSPERO) 05 July 2020.</p>","PeriodicalId":22046,"journal":{"name":"Supportive Care in Cancer","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142584380","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Chiho Moon, Hyounmin Kim, Jin Hoo Park, Wonse Park, Hyung Jun Kim, Young-Soo Jung, Jun-Young Kim
{"title":"High-dose denosumab (Xgeva®) Associated Medication-Related Osteonecrosis of the Jaws (MRONJ): incidence and clinical characteristics in a retrospective analysis of 1278 patients.","authors":"Chiho Moon, Hyounmin Kim, Jin Hoo Park, Wonse Park, Hyung Jun Kim, Young-Soo Jung, Jun-Young Kim","doi":"10.1007/s00520-024-08974-6","DOIUrl":"https://doi.org/10.1007/s00520-024-08974-6","url":null,"abstract":"<p><strong>Purpose: </strong>High-dose denosumab (Xgeva®) is increasingly used for treating bone metastasis and various malignant diseases but carries the risk of medication-related osteonecrosis of the jaw (MRONJ). This study aimed to evaluate the incidence, risk factors, and clinical outcomes of MRONJ in patients treated with high-dose denosumab.</p><p><strong>Methods: </strong>A retrospective review was performed on 1278 patients who received high-dose denosumab at Severance Hospital, Seoul, South Korea, from September 2014 to February 2023. Data on the incidence of MRONJ, patient demographics, primary diseases, and treatment outcomes were analyzed.</p><p><strong>Results: </strong>Among the 1278 patients (average age 64.72 years; 728 males and 550 females) treated, 34 developed MRONJ, with a 2.66% incidence rate. The average age of those with MRONJ was 68.32 years, and they received more Xgeva® injections on average (13.62) compared to the overall cohort. Factors such as age and the frequency of injections were significantly associated with the risk of MRONJ. Notably, the incidence of MRONJ did not significantly differ between those who underwent oral surgery and those with spontaneous MRONJ, especially if oral surgery occurred within 1 month of injection. Surgical interventions have shown higher recovery rates in advanced MRONJ stages.</p><p><strong>Conclusion: </strong>This study confirmed a significant MRONJ incidence of 2.66% among high-dose denosumab recipients, highlighting the importance of careful patient selection, monitoring, and education, particularly in older and long-term treatment patients, to mitigate the risk of MRONJ.</p>","PeriodicalId":22046,"journal":{"name":"Supportive Care in Cancer","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142584377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Tomohiro F Nishijima, Mototsugu Shimokawa, Tomoko Hamabe, Masato Komoda, Yuta Okumura, Kohei Arimizu, Masaru Morita, Taito Esaki, Kirsten A Nyrop
{"title":"Development of a Leg And Walking Self-exercise (LAWS) program for older adults during cancer treatment.","authors":"Tomohiro F Nishijima, Mototsugu Shimokawa, Tomoko Hamabe, Masato Komoda, Yuta Okumura, Kohei Arimizu, Masaru Morita, Taito Esaki, Kirsten A Nyrop","doi":"10.1007/s00520-024-08965-7","DOIUrl":"https://doi.org/10.1007/s00520-024-08965-7","url":null,"abstract":"<p><strong>Purpose: </strong>We developed a self-directed Leg And Walking Self-exercise (LAWS) program informed by the Exercise is Medicine initiative and evaluated the feasibility and acceptability of this program in older adults with cancer.</p><p><strong>Methods: </strong>Over a 1-year period, we prospectively enrolled 40 older adults who received a comprehensive geriatric assessment (CGA) at a geriatric oncology service and initiated a new line of systemic therapy for advanced cancer as inpatients. LAWS is a tailored, self-directed exercise program consisting of leg resistance training and walking. Exercise adherence was recorded using an exercise diary to assess feasibility. Patient perspectives on this program were evaluated using the Feasibility of Intervention Measure (FIM) and Acceptability of Intervention Measure (AIM), with a score range of 1-5, higher being better.</p><p><strong>Results: </strong>Overall, 28% of patients were fit, 53% pre-frail, and 20% frail based on the CGA. During hospitalization (average 12 days), 63% of the patients adhered to exercises at lowest intensity during more than 50% of their inpatient stay: on average, 2.8 leg exercises, 23 repetitions a day, 5.6 days/week, and 19 min of walking a day, 4.9 days/week. Patients rated their perceived exertion at 3.0 for leg exercise and 3.0 for walking on a 1-10 Likert scale. During the period between discharge and their first outpatient appointment (average 11 days), 71% of patients adhered to the LAWS program. Mean scores of FIM and AIM were 4.2 (SD = 0.5) and 4.2 (SD = 0.7), respectively.</p><p><strong>Conclusions: </strong>For older adults undergoing cancer treatment, LAWS is a feasible and acceptable self-directed exercise program.</p>","PeriodicalId":22046,"journal":{"name":"Supportive Care in Cancer","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142584376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Charlotte Gerrity, Abdulrahman Sinno, Akina Natori, Vandana Sookdeo, Jessica MacIntyre, Sophia George, Carmen Calfa, Tracy E Crane, Frank J Penedo, Matthew Schlumbrecht
{"title":"Patterns of patient-reported outcomes (PROs) in a diverse group of gynecologic cancer survivors.","authors":"Charlotte Gerrity, Abdulrahman Sinno, Akina Natori, Vandana Sookdeo, Jessica MacIntyre, Sophia George, Carmen Calfa, Tracy E Crane, Frank J Penedo, Matthew Schlumbrecht","doi":"10.1007/s00520-024-08968-4","DOIUrl":"10.1007/s00520-024-08968-4","url":null,"abstract":"<p><strong>Objectives: </strong>Racial and ethnic disparities in patient-reported outcomes (PROs) among gynecologic cancer survivors are not well studied. We evaluated whether individual-level characteristics were associated with PROs in diverse gynecologic cancer survivors.</p><p><strong>Methods: </strong>Gynecologic cancer patients in an ambulatory oncology clinic completed a psychosocial and practical needs assessment before their appointments through the electronic medical record (EMR) patient portal. Assessments were available in English and Spanish. Fatigue, pain, physical function, depression, and anxiety were assessed with Patient-Reported Outcomes Measurement Information System (PROMIS®) computer adaptive tests, and health-related quality of life was assessed by FACT-G7. PROs were dichotomized based on severity (normal/mild vs moderate/severe). Demographic and clinical information was collected. Analyses were performed using Chi-square, t-tests, and Kruskal-Wallis tests.</p><p><strong>Results: </strong>A total of 582 women completed the assessment; 20% (n = 116) were racial minorities, and 54.5% (n = 310) were Hispanic. A total of 192 (32.8%) completed the assessments in Spanish. Hispanic patients had lower mean fatigue scores (49.31 vs 51.74, p = 0.01), and patients whose preferred language was Spanish had lower mean depression (47.63 vs 48.97, p = 0.05) and fatigue scores (48.27 vs 51.27, p < 0.01). There were no significant differences in the severity of PROs by race, ethnicity, or preferred language. QOL scores were worse in patients with high symptom severity for anxiety (p = 0.04) and physical functioning (p < 0.01). Current smokers had worse physical functioning (13.4% vs 6.5%, p = 0.03).</p><p><strong>Conclusions: </strong>We found no significant differences in severity of PROs by race, ethnicity, or preferred language. Quality of life scores were worse for patients with high symptom severity for physical functioning and anxiety.</p>","PeriodicalId":22046,"journal":{"name":"Supportive Care in Cancer","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11535011/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142576947","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pierre Pouvreau, Imed Taleb, Agathe Fontaine, Lucas Edouard, Nyere Gibson, Margaux Yaouanq, Augustin Boudoussier, Adeline Petit, Vincent Vinh-Hung, Paul Sargos, Nicolas Benziane-Ouaritini, Wafa Bouleftour, Nicolas Magne
{"title":"Heart is a heavy burden: cardiac toxicity in radiation oncology.","authors":"Pierre Pouvreau, Imed Taleb, Agathe Fontaine, Lucas Edouard, Nyere Gibson, Margaux Yaouanq, Augustin Boudoussier, Adeline Petit, Vincent Vinh-Hung, Paul Sargos, Nicolas Benziane-Ouaritini, Wafa Bouleftour, Nicolas Magne","doi":"10.1007/s00520-024-08949-7","DOIUrl":"https://doi.org/10.1007/s00520-024-08949-7","url":null,"abstract":"<p><p>Over the years, radiotherapy has seen continual improvements and has become a standard treatment for most malignant tumors. Cardiotoxicity is a well-known radiotherapy side effect, leading to the risk of long-term morbidity and mortality in cancer survivors. Therefore, minimizing radiotherapy-related cardiotoxicity remains an important challenge in cancer care management. Indeed, multiple dose constraints were proposed for the heart and its substructures. In addition, sparing techniques were developed to reduce the exposure of the heart to ionizing radiation and are currently used in daily clinical routine. The purpose of this review is to summarize the current knowledge about radiation-induced cardiotoxicity, to discuss the previously cardiac dose constraints, and to evaluate the various management strategies.</p>","PeriodicalId":22046,"journal":{"name":"Supportive Care in Cancer","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142569538","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Karine Lima Kido de Carvalho, Alessandra Nogueira Porto, Andreza Maria Fabio Aranha, Gileade Pereira Freitas, Luiz Evaristo Ricci Volpato
{"title":"Evaluation of A. actinomycetemcomitans and P. gingivalis from the mouth of patients irradiated in the head and neck region: a cross-sectional study.","authors":"Karine Lima Kido de Carvalho, Alessandra Nogueira Porto, Andreza Maria Fabio Aranha, Gileade Pereira Freitas, Luiz Evaristo Ricci Volpato","doi":"10.1007/s00520-024-08970-w","DOIUrl":"https://doi.org/10.1007/s00520-024-08970-w","url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to quantify Aggregatibacter actinomycetemcomitans (A.a) and Porphyromonas gingivalis (P.g) from the mouth of head and neck irradiated and cancer-free patients.</p><p><strong>Methods: </strong>Information such as age, presence of tongue coating, salivary flow, and biofilm were collected from head and neck irradiated patients (Group 1) and compared the results with a group of cancer-free individuals (Group 2). The presence of tongue coating was clinically examined. Sialometry was performed through a stimulating technique by chewing paraffin. Microbiological samples were collected from buccal and labial mucosa and tongue dorsum. Subsequently, the samples were processed and analyzed by qPCR to detect the presence and quantify the bacteria.</p><p><strong>Results: </strong>There was a statistical difference in the quantity of bacteria among the 24 individuals in Group 1 (A.a, 2817 ± 8718; P.g, 3145 ± 11297) and 26 individuals in Group 2 (A.a, 133996 ± 398545; P.g, 60 ± 195) regarding tongue coating (Group 1, A.a 2194.6 ± 4641.5; Group 2, A.a 92767.8 ± 333385.7) and salivary volume (Group 1, 0.69 mL; Group 2, 3.09 mL). The linear regression analysis found that the variable group was the main responsible for the difference in the quantity of periodontal pathogens (p-value < 0.001). There was no statistical difference in the amount of Aggregatibacter actinomycetemcomitans and Porphyromonas gingivalis between totally edentulous and partially edentulous (with 12 or fewer teeth) patients.</p><p><strong>Conclusion: </strong>Aggregatibacter actinomycetemcomitans and Porphyromonas gingivalis were present in significant amounts in patients of both groups, with a greater quantity in cancer-free individuals.</p>","PeriodicalId":22046,"journal":{"name":"Supportive Care in Cancer","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142576946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Demi M Kruimer, Debbie C Stavleu, Renée L Mulder, Leontien C M Kremer, Wim J E Tissing, Erik A H Loeffen
{"title":"Prophylactic red blood cell transfusions in children and neonates with cancer: An evidence-based clinical practice guideline.","authors":"Demi M Kruimer, Debbie C Stavleu, Renée L Mulder, Leontien C M Kremer, Wim J E Tissing, Erik A H Loeffen","doi":"10.1007/s00520-024-08888-3","DOIUrl":"10.1007/s00520-024-08888-3","url":null,"abstract":"<p><strong>Background: </strong>Red blood cell (RBC) transfusions play an important role in supportive care in children and neonates with cancer. However, in current clinical practice, evidence-based recommendations are lacking on when to administer prophylactic RBC transfusions. To address this gap, a clinical practice guideline (CPG) was developed to systematically review the available evidence and provide recommendations for clinicians.</p><p><strong>Methods: </strong>A systematic literature review in three databases was conducted. The GRADE methodology was used to assess, extract, and summarize the evidence. A multidisciplinary panel of 21 professionals was assembled to ensure comprehensive expertise. If there was insufficient evidence in children with cancer, additional evidence was gathered in general pediatric or adult oncology guidelines, or the panel utilized shared expert opinion to develop a comprehensive CPG. Multiple in-person meetings were conducted to discuss evidence, complete evidence-to-decision frameworks, and formulate recommendations.</p><p><strong>Results: </strong>Four studies including 203 children with all types of cancer, met the inclusion criteria. The expert panel assessed all evidence and translated it into recommendations. In total, 47 recommendations were formulated regarding RBC transfusions in children and neonates with cancer. For instance, specific thresholds for prophylactic RBC transfusions were recommended for children and neonates with cancer who have sepsis, are on ECMO, or are undergoing radiotherapy.</p><p><strong>Conclusion: </strong>This clinical practice guideline presents evidence-based recommendations regarding RBC transfusions in children and neonates with cancer. By providing these recommendations, we aim to guide clinicians and contribute to improving outcomes for children and neonates with cancer.</p>","PeriodicalId":22046,"journal":{"name":"Supportive Care in Cancer","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11534970/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142569541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Milena Gojsevic, Thenugaa Rajeswaran, Liying Zhang, Samantha K F Kennedy, Irene Karam, Keyue Ding, Patries Herst, Henry Wong, Jennifer Y Y Kwan, Amir H Safavi, Jacqueline Lam, Silvana Spadafora, Natalie Walde, Katherine Carothers, Francois Gallant, Tara Behroozian, Emily Lam, Edward Chow
{"title":"Concordance of patient- and clinician-reported outcomes of acute radiation dermatitis in breast cancer.","authors":"Milena Gojsevic, Thenugaa Rajeswaran, Liying Zhang, Samantha K F Kennedy, Irene Karam, Keyue Ding, Patries Herst, Henry Wong, Jennifer Y Y Kwan, Amir H Safavi, Jacqueline Lam, Silvana Spadafora, Natalie Walde, Katherine Carothers, Francois Gallant, Tara Behroozian, Emily Lam, Edward Chow","doi":"10.1007/s00520-024-08966-6","DOIUrl":"https://doi.org/10.1007/s00520-024-08966-6","url":null,"abstract":"<p><strong>Background and purpose: </strong>The study evaluated the concordance between patient-reported outcomes (PRO) and clinician-reported outcomes (CRO) of acute radiation dermatitis (RD) symptoms following adjuvant radiotherapy for early-stage and locally advanced breast cancer.</p><p><strong>Material and methods: </strong>This is a secondary analysis of a multi-center randomized phase 3 trial (376 patients). Ordinal logistic regression analysis was used to compare the Skin Symptom Assessment (SSA) independently reported by both patients and clinicians. Concordance between patient- and clinician-reported SSAs for RD symptoms was measured by percent concordance, concordance index (C-statistic), and Cohen's Kappa. Analyses were performed across all patients in the original modified intention-to-treat analysis and those with only grade 2-3 (CTCAE) RD.</p><p><strong>Results: </strong>PROs were significantly more severe than CROs across all RD symptoms (Odds Ratio [OR] > 1; p < 0.0001). Pigmentation (OR 5.4), blistering/peeling (OR 4.0), and pain/soreness (OR 3.9) were the most differentially reported symptoms. Poor-to-low concordance was noted between patient- and clinician-reported SSAs for all RD symptoms for the entire cohort (percent concordance < 50%, C-statistic 0.52-0.63, Cohen's Kappa 13.9-23.4%) and those with grade 2-3 RD (percent concordance < 50%, C-statistic 0.56-0.66, Cohen's Kappa 2.0-24.5%). Similarly, poor-to-low concordance was noted in both Mepitel film and standard-of-care arms.</p><p><strong>Conclusion: </strong>PROs and CROs have poor concordance in breast RD, and patients report worse outcomes than clinicians, regardless of RD severity or prophylaxis. PROs must be further integrated into routine clinical practice and clinical trial design to reduce the risk of underreporting symptoms.</p>","PeriodicalId":22046,"journal":{"name":"Supportive Care in Cancer","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142569537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Sexual health counseling improves the sexual satisfaction of breast cancer survivors: a randomized controlled trial.","authors":"Fatemeh Razeghi Haghighi, Mahshid Bokaie, Reyhane Sefidkar, Behnaz Enjezab","doi":"10.1007/s00520-024-08957-7","DOIUrl":"10.1007/s00520-024-08957-7","url":null,"abstract":"<p><strong>Purpose: </strong>Breast cancer and its treatments can cause sexual problems both physically and psychologically by the changes it brings. This study aimed to investigate the effect of sexual health counseling based on acceptance and commitment therapy (ACT) on the sexual satisfaction of women with chemotherapy-induced menopause (CIM) in breast cancer survivors.</p><p><strong>Methods: </strong>Seventy women with CIM were randomly divided into two intervention (N = 34) and control (N = 36) groups. The intervention group attended eight sessions of 90-min sexual health counseling based on ACT. The control group received an educational booklet. The Sexual Satisfaction Scale for Women(SSS-W), the Sexual Quality of Life-Female questionnaire(SQOL-F), and the Menopause Rating Scale(MRS) were used to collect data before, after, and 1 month after the intervention in both groups.</p><p><strong>Results: </strong>The mean score of sexual satisfaction (F = 45.67, P < 0.001) and sexual quality of life (F = 33.39, P < 0.001) were significantly higher after the intervention and follow-up than before intervention in the intervention group. Also, the mean score of menopausal symptoms was significantly lower after the intervention and follow-up than before intervention in the intervention group (F = 11.80, P < 0.001). However, the mean score of sexual satisfaction (F = 0.02, P = 0.98), sexual quality of life (F = 0.05, P = 0.94), and menopausal symptoms (F = 0.08, P = 0.92) did not show significant differences before, after, and 1 month after the intervention in the control group.</p><p><strong>Conclusions: </strong>Therefore, sexual health counseling based on ACT seems to have salutary effect on sexual satisfaction, sexual quality of life, and menopausal symptoms of women with breast cancer who experience CIM.</p><p><strong>Trial registration: </strong>This randomized control trial has been approved by Iranian Registry of Clinical Trials, IRCT20230105057055N1 at 2023-01-29.</p>","PeriodicalId":22046,"journal":{"name":"Supportive Care in Cancer","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142569545","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}